<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="367188">
  <stage>Registered</stage>
  <submitdate>1/10/2014</submitdate>
  <approvaldate>10/11/2014</approvaldate>
  <actrnumber>ACTRN12614001177640</actrnumber>
  <trial_identification>
    <studytitle>Effect of a package of care on outcomes in patients with gout</studytitle>
    <scientifictitle>Effect of a package of care on serum urate levels in gout patients in a rural general practice setting</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>NIL</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Gout</healthcondition>
    <conditioncode>
      <conditioncode1>Musculoskeletal</conditioncode1>
      <conditioncode2>Other muscular and skeletal disorders</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Inflammatory and Immune System</conditioncode1>
      <conditioncode2>Other inflammatory or immune system disorders</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Patients with gout receive a package of care from the GP which represents best clinical practice (based on ACR and EULAR guidelines). This will include 
1. medication for acute gout as well as long term urate lowering therapy - this may be no different from the historical controls other than more focus on achieving appropriate treatment targets 
2. education about the causes and management of gout - unknown what the controls received
3. screening for co-morbidities associated with gout including heart disease, diabetes and kidney disease - unknown what the controls received. 
There is no specified treatment period as this is individualised The only proceedures outside of nornal clinical practice are that we will monitor whether patients take allopurinol (one form of urate lowering medication) through blood tests.</interventions>
    <comparator>Will will compare outcomes with retrospective data from the same medical practice. Treatment in the historical control group was at the discretion of the treating general practitioner. The audit will determine how appropriate and successful this was. Historical data will be collected from 1/1/2012-31/12/2012 -</comparator>
    <control>Historical</control>
    <interventioncode>Not applicable</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Number of patients on urate lowering therapy from medication records and though blood tests</outcome>
      <timepoint>12 months</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Number of patients with serum urate &lt;0.36mmol/l</outcome>
      <timepoint>12 months</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Number of gout patients screened for  comorbidities associated with gout from medical records</outcome>
      <timepoint>12 months</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Gout</inclusivecriteria>
    <inclusiveminage>0</inclusiveminage>
    <inclusiveminagetype>No limit</inclusiveminagetype>
    <inclusivemaxage>0</inclusivemaxage>
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>Unwilling to provide consent</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Observational</studytype>
    <purpose />
    <allocation />
    <concealment />
    <sequence />
    <masking />
    <assignment />
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry>False</patientregistry>
    <followup />
    <followuptype />
    <purposeobs>Natural history</purposeobs>
    <duration>Longitudinal</duration>
    <selection>Defined population</selection>
    <timing>Both</timing>
  </trial_design>
  <recruitment>
    <phase>Not Applicable</phase>
    <anticipatedstartdate>17/11/2014</anticipatedstartdate>
    <actualstartdate>5/01/2015</actualstartdate>
    <anticipatedenddate />
    <actualenddate>6/10/2015</actualenddate>
    <samplesize>90</samplesize>
    <actualsamplesize>68</actualsamplesize>
    <recruitmentstatus>Completed</recruitmentstatus>
    <anticipatedlastvisitdate>15/09/2016</anticipatedlastvisitdate>
    <actuallastvisitdate>31/12/2016</actuallastvisitdate>
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>,Outside</recruitmentcountry>
    <recruitmentstate />
    <countryoutsideaustralia>
      <country>New Zealand</country>
      <state>Canterbury</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>University</primarysponsortype>
    <primarysponsorname>University of Otago</primarysponsorname>
    <primarysponsoraddress>POBox 4345
Christchurch 8014</primarysponsoraddress>
    <primarysponsorcountry>New Zealand</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Government body</fundingtype>
      <fundingname>Health Research Council of New Zealand</fundingname>
      <fundingaddress>PO Box 5541
Wellesley Street
Auckland 1141</fundingaddress>
      <fundingcountry>New Zealand</fundingcountry>
    </fundingsource>
    <fundingsource>
      <fundingtype>Hospital</fundingtype>
      <fundingname>Canterbury District Health Board</fundingname>
      <fundingaddress>Private Bag 4710
Christchurch 8014
New Zealand</fundingaddress>
      <fundingcountry>New Zealand</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname />
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>Gout is a common problem particularly in New Zealand. The majority of patients with gout are managed in primary care. Guidelines for management are well established and there are effective medications to prevent gout, but few patients achieve treatment targets, leading to painful gout attacks and eventual joint damage. We have implemented an integrated package of care, designed to be delivered in general practice that incorporates education, gout treatment and appropriate screening and management of important co-morbidities associated with gout such as heart disease and diabetes. Herein we will examine the effetcs of the package of care in a rural general practice setting, Kaikoura. We will determine whether more patients reach treatment targets and are screened for and where appropriate receive treatment for co-morbidities. Outcomes will be compared to retrospective data from the same medical practice.</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Health and Disability Ethics Committee of New Zealand</ethicname>
      <ethicaddress>PO Box 5013
Wellington 6011</ethicaddress>
      <ethicapprovaldate>28/10/2014</ethicapprovaldate>
      <hrec>14/CEN/163</hrec>
      <ethicsubmitdate>5/10/2014</ethicsubmitdate>
      <ethiccountry>New Zealand</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title>Prof</title>
      <name>Lisa Stamp</name>
      <address>POBox 4345
University of Otago, Christchurch
Christchurch 8014</address>
      <phone>+ 64 3 364 0253</phone>
      <fax />
      <email>lisa.stamp@cdhb.health.nz</email>
      <country>New Zealand</country>
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title>Prof</title>
      <name>Lisa Stamp</name>
      <address>POBox 4345
University of Otago, Christchurch
Christchurch 8014</address>
      <phone>+ 64 3 364 0253</phone>
      <fax />
      <email>lisa.stamp@cdhb.health.nz</email>
      <country>New Zealand</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title>Prof</title>
      <name>Lisa Stamp</name>
      <address>POBox 4345
University of Otago, Christchurch
Christchurch 8014</address>
      <phone>+ 64 3 364 0253</phone>
      <fax />
      <email>lisa.stamp@cdhb.health.nz</email>
      <country>New Zealand</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title>Prof</title>
      <name>Lisa Stamp</name>
      <address>POBox 4345
University of Otago, Christchurch
Christchurch 8014</address>
      <phone>+ 64 3 3640253</phone>
      <fax />
      <email>lisa.stamp@cdhb.health.nz</email>
      <country>New Zealand</country>
      <type>Updating Information</type>
    </contact>
  </contacts>
</ANZCTR_Trial>